Myles HelfandExecutive Editor
Myles is the executive editor and general manager of TheBody/TheBodyPro. A career journalist and editor, Myles joined TheBody in 2001 as a part-time copyeditor. He has since established himself as a leading journalist and content strategist on HIV-related issues, authoring hundreds of articles and editing hundreds more -- and accumulating an ever-growing mountain of HIV conference badges along the way.
Latest by Myles Helfand
April 2, 2020: Physical activity vs. heart med adherence; reducing the burden of HIV emergency care; increasing smoking cessation intervention success; virologic failure following asymptomatic HIV treatment initiation.
March 26, 2020: Lopinavir/ritonavir falls short against COVID-19; impact of PrEP scale-up on HIV diagnoses; long-term cost-effectiveness of various HIV interventions; disparities in virologic suppression among young people.
Multiple U.S. health agencies have released HIV-specific information, and research on HIV and the novel coronavirus is trickling in. Here's what health care providers need to know.
March 19, 2020: Mood disorders and metabolic syndrome; comorbidity burden among women living with HIV; two-year weight gain after switching to integrase; long-term adipose tissue density trends.
Recent Initiation of Testosterone Therapy Linked to Greater Atherosclerosis Progression in MSM With HIV
New findings contribute to the indication that people with HIV taking testosterone therapy should be counseled on the cardiovascular risks.
The biggest may be that more of an HIV-positive person’s equally long lifespan will be spent managing comorbidities, one large study found.
March 12, 2020: The impact of age on viral suppression and immunologic recovery; chronic obstructive pulmonary disease risk among older PLWHIV; sex-based differences in older men vs. women; effect of aging on drug-drug interactions.
With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.
March 5, 2020: How U=U reduces more than HIV transmission; "other" HPV strain risks post-vaccination; vitamin E for nonalcoholic steatohepatitis; HCV therapy and increased cardiovascular risk.